Myolex
Dave Dickinson serves as the Chief Executive Officer of Myolex, where innovative technology aims to transform the measurement and treatment of muscle wasting related to obesity, aging, and sports injuries. In addition, Dave holds a voluntary role as Venture Mentor and Entrepreneur in Residence at Beth Israel Deaconess Medical Center, contributing to the translation of research into societal benefits. Previous experiences include founding Milestone Crossing LLC, leading Tausight to launch a groundbreaking PHI awareness platform, and various executive positions at UnitedHealth Group, Healthrageous, Zeo, StemCyte, Pericor Science, and Bristol-Myers Squibb, showcasing a robust background in healthcare innovation, business development, and venture growth. Dave holds a BS in Industrial Economics from Union College and has further education from the Kellogg School of Management at Northwestern University.
This person is not in any teams
Myolex
Myolex is disrupting how to measure muscle wasting (and treatment), caused by obesity drugs, aging, and sport injuries. Myolex® EIM is a patented device technology and SaaS data analytics platform that is built to disrupt skeletal muscle measurement by becoming the clinical and wellness standard to aid in the diagnosis and treatment of obesity drug and age-related muscle wasting. Myolex has developed the 1st quantitative, sensitive, painless, portable for home use muscle quality assessment device that is specifically designed to non-invasively, comprehensibly, and precisely detect and monitor single muscle wasting.